Eaton Vance Management’s Bio-Rad Laboratories Class A BIO Stock Holding History

Eaton Vance Management’s Portfolio BIO Stock Details BIO Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q3	$2.69M	Buy	6,452 +104	+2%	+$51.9K	﹤0.01%	958
2022 Q2	$3.14M	Sell	6,348 -6,038	-49%	-$3.14M	﹤0.01%	936
2022 Q1	$6.98M	Buy	12,386 +9,794	+378%	+$5.9M	0.01%	795
2021 Q4	$1.96M	Buy	2,592 +129	+5%	+$96.5K	﹤0.01%	1029
2021 Q3	$1.16M	Buy	2,463 +1,249	+103%	+$936K	﹤0.01%	1059
2021 Q2	$781K	Buy	1,214 +1,023	+536%	+$623K	﹤0.01%	1241
2021 Q1	$109K	Buy	+191	New	+$113K	﹤0.01%	1583

Other funds holding BIO

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VAM

Veritas Asset Management London, United Kingdom $5.9B AUM 3.19% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Brown Advisory Baltimore, Maryland $60.9B AUM 15.24% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

AllianceBernstein Nashville, Tennessee $309B AUM 23.92% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return

Eaton Vance Management's BIO Position: Q3 2022 in Review

Eaton Vance Management increased its Bio-Rad Laboratories Class A (BIO) stake by 1.6% in Q3 2022, buying an estimated $51.9K and bringing the position to 6,452 shares worth $2.69M. The position accounts for ﹤0.01% of the portfolio, ranked #958.

Eaton Vance Management first reported a position in BIO in Q1 2021 and has held it in 7 quarters since. The position peaked at $6.98M in Q1 2022. 485 funds tracked by Wall St. Rank hold BIO as of Q3 2022.

Eaton Vance Management held 6,452 shares of Bio-Rad Laboratories Class A worth $2.69M as of Q3 2022.
Eaton Vance Management bought 104 Bio-Rad Laboratories Class A shares in Q3 2022, an estimated $51.9K.
Bio-Rad Laboratories Class A made up ﹤0.01% of Eaton Vance Management's portfolio in Q3 2022, its #958 holding.
Eaton Vance Management first reported a position in Bio-Rad Laboratories Class A in Q1 2021 and has held it in 7 quarters since.
Eaton Vance Management's Bio-Rad Laboratories Class A position peaked at $6.98M in Q1 2022.
485 funds tracked by Wall St. Rank held Bio-Rad Laboratories Class A as of Q3 2022.

Based on Eaton Vance Management's 13F filing for Q3 2022, filed 14 Nov 2022.